Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 7/20 | 0.81 |
| ▸ | RAB9A | P51151 | 6/20 | 0.81 |
| ▸ | NPC1 | O15118 | 5/20 | 0.81 |
| ▸ | LMNA | P02545 | 2/20 | 0.81 |
| ▸ | GAA | P10253 | 1/20 | 0.81 |
| ▸ | CYP11B1 | P15538 | 5/20 | 0.73 |
| ▸ | CYP11B2 | P19099 | 5/20 | 0.73 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.67 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.63 |
| ▸ | TP53 | P04637 | 1/20 | 0.62 |
| ▸ | RECQL | P46063 | 1/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14082510 | 0.89 | NAMPT (0.88) | NAMPTRAB9ANPC1LMNAGAA | |
| SCHEMBL5944173 | 0.85 | KCNK3 (0.67) | NAMPTRAB9ANPC1LMNAGAA | |
| SCHEMBL6354168 | 0.84 | CYP11B1 (1.00) | NAMPTRAB9ANPC1LMNAGAA | |
| SCHEMBL3017773 | 0.84 | CYP11B1 (0.63) | NAMPTRAB9ANPC1LMNAGAA | |
| SCHEMBL1109339 | 0.84 | MKNK1 (0.73) | NAMPTRAB9ANPC1LMNAGAA | |
| SCHEMBL5435462 | 0.83 | NAMPT (0.76) | NAMPTRAB9ANPC1LMNAGAA | |
| SCHEMBL3642636 | 0.83 | NAMPT (0.81) | NAMPTRAB9ANPC1LMNAGAA | |
| SCHEMBL28007807 | 0.82 | NAMPT (0.81) | NAMPTRAB9ANPC1LMNAGAA | |
| SCHEMBL167081 | 0.82 | NAMPT (1.00) | NAMPTRAB9ANPC1LMNAGAA | |
| SCHEMBL14082506 | 0.82 | NAMPT (0.86) | NAMPTRAB9ANPC1LMNAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100216796-A1 | N-HYDROXY-NAPHTHALENE DICARBOXAMIDE AND N-HYDROXY-BIPHENYL-DICARBOXAMIDE COMPOUNDS AS HISTONE DEACETYLASE INHIBITORS | KATTAR SOLOMON | 2010-08-26 | — | — | US | claimed |
| US-20100216796-A1 | N-HYDROXY-NAPHTHALENE DICARBOXAMIDE AND N-HYDROXY-BIPHENYL-DICARBOXAMIDE COMPOUNDS AS HISTONE DEACETYLASE INHIBITORS | KATTAR SOLOMON | 2010-08-26 | — | — | US | disclosed |
| EP-2205070-A1 | N-HYDROXY-NAPHTHALENE DICARBOXAMIDE AND N-HYDROXY-BIPHENYL-DICARBOXAMIDE COMPOUNDS AS HISTONE DEACETYLASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2010-07-14 | — | — | EP | disclosed |
| WO-2009045385-A1 | N-HYDROXY-NAPHTHALENE DICARBOXAMIDE AND N-HYDROXY-BIPHENYL-DICARBOXAMIDE COMPOUNDS AS HISTONE DEACETYLASE INHIBITORS | MERCK & CO., INC. (US) | 2009-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216796-A1 | N-HYDROXY-NAPHTHALENE DICARBOXAMIDE AND N-HYDROXY-BIPHENYL-DICARBOXAMIDE COMPOUNDS AS HISTONE DEACETYLASE INHIBITORS | BRDT, AADAC, ACIN1 | NAMPT 347/4885RAB9A 4531/4885NPC1 2497/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.